Related Experiment Video
Updated: Mar 14, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer
Charalampos Fragkoulis1, Ioannis Gkialas, Georgios Papadopoulos
1Department of Urology, General Hospital of Athens G.N.A "G. Gennimatas", Athens, Greece.
Abstract:
Prostate cancer is a major public health problem worldwide, still remaining the most common cancer among elder males in both Europe and USA, being responsible for approximately 30,000 deaths in USA in 2014. Nowadays, after decades of basic research, novel treatment options have emerged focusing on men suffering from metastatic castration-resistant prostate cancer improving overall survival. It is also estimated that more than 90% of such patients develop bone metastasis, resulting in a significant increase in morbidity and mortality. The purpose of this review was to discuss the treatment options targeting bone metastasis in castration-resistant prostate cancer patients by examining the available literature focusing primarily in the role of zoledronic acid, denosumab and radium 223.
Insights
Prostate cancer significantly impacts elder males, with bone metastasis common in castration-resistant cases. This review examines treatments like zoledronic acid, denosumab, and radium 223 for bone metastasis in prostate cancer.
Area of Science:
- Oncology
- Urology
- Bone Metastasis Research
Background:
- Prostate cancer is a leading cause of death in elder males globally, particularly in Europe and the USA.
- Metastatic castration-resistant prostate cancer (mCRPC) presents significant survival challenges.
- Bone metastasis is prevalent in over 90% of mCRPC patients, increasing morbidity and mortality.
Purpose of the Study:
- To review current treatment strategies for bone metastasis in castration-resistant prostate cancer.
- To evaluate the efficacy of key therapeutic agents in managing bone metastases.
Main Methods:
- Literature review of available studies on prostate cancer bone metastasis treatments.
- Focus on zoledronic acid, denosumab, and radium 223.
- Analysis of treatment outcomes and survival data.
Main Results:
- Zoledronic acid and denosumab are established bone-targeting agents for mCRPC.
- Radium 223 shows promise in improving survival for mCRPC patients with bone metastases.
- These treatments aim to reduce skeletal-related events and improve patient quality of life.
Conclusions:
- Targeted therapies are crucial for managing bone metastasis in mCRPC.
- Zoledronic acid, denosumab, and radium 223 represent important options for clinicians.
- Further research is needed to optimize treatment sequencing and combination strategies.
More Related Videos
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...